During the two-year preparation module phase, the Einstein Foundation will be funding the innovative research field of cell-based interceptive medicine. New, promising research approaches aim to diagnose and fight diseases at a very early stage, when there are only a few diseased cells present in the patient and they are not yet displaying symptoms or complications. The focus of the planned cross-institutional center will be on the accelerated development, integration, and application of new key technologies in the areas of single-cell multiomics and spatial biology, advanced pre-clinical patient models, and novel solutions that make use of artificial intelligence. The consortium brings together researchers and clinicians from ten leading Berlin institutions, including Charité and the Berlin Institute of Health at Charité (BIH), the Max Delbrück Center, Technische Universität Berlin (TU Berlin), FU Berlin, HU Berlin, the Museum für Naturkunde, and the Max Planck Institute for Molecular Genetics.
